There is no approved treatment for Hunter syndrome in China, unlike in some parts of the world.
Hunter syndrome (Mucopolysaccharidosis type II) is an inherited lysosomal storage disease that occurs primarily in boys. It causes an enzyme deficiency that interferes with the body's ability to break down certain complex sugars, resulting in serious skeletal, tissue, neurological and multi-organ complications and, ultimately, death.
It occurs in approximately 1.3 out of 100,000 male newborns.
There is no cure. The standard treatments are enzyme replacement therapy or palliative care. Mucopolysaccharidosis is one of the 121 diseases on the China Rare Disease List recently published by the Chinese government.
GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines.
Headquartered in South Korea, GC Pharma is one of the largest protein products manufacturers in the world and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corp. updates its corporate brand as GC Pharma in early 2018.
Green Cross Corp. remains the company's registered, legal name.
CANbridge Pharmaceuticals is a China-based biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.
The company is a specialist in orphan diseases in China, and has a partnership with WuXi Biologics to develop and commercialise proprietary therapeutics for the treatment of rare diseases.
CANbridge also has exclusive rights to develop and commercialise Puma biotechnology's Nerlynx (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China); a license with Apogenix to develop and commercialise APG101 in greater China; a license (ex-North America) to develop and commercialize AVEO Oncology's ErbB3 inhibitory antibody candidate AV203 and an agreement with EUSA Pharma to commercialise Caphosol for the prevention and treatment of oral mucositis caused by cancer treatments, for which it has received approval in China.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine